title: Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight
source: Yahoo
date: 2025-10-06
url: https://finnhub.io/api/news?id=3a96d673fad800ab7302636a8b19c3c5b521809503cde1f57b653700adb5158f
The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing a significant unmet need. The development pipeline is varied, with prominent candidates including Mitsubishi Tanabe Pharma’s MT-7117, Cumberland’s ifetroban, Johnson & Johnson’s guselkumab, and Kyverna’s KYV-101. The dcSSc market is anticipated to move toward earlier intervention with targeted thera
